ArticlePituitary2026
COPeptin Evaluation in argininevasopressin Deficiency post transsphenoidal surgery (COPED study).
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCopeptin is an emerging biomarker for polyuria-polydipsia syndrome. Postoperative copeptin levels may predict acquired arginine vasopressin deficiency (AVP-D). This prospective study evaluated the diagnostic performance of serum copeptin for predicting postoperative AVP-D after transsphenoidal surgery (TSS).
methodsCopeptin was measured preoperatively, immediately after surgery (periextubation, T0), upon first ward arrival (T1), daily until discharge, and at week 2. Delta copeptin was calculated as the percentage change from T0 to T1.
resultsOf 53 patients, 23 (43.4%) developed AVP-D, including 4 (7.5%) permanent and 19 (35.8%) transient cases. The AVP-D group showed significantly lower delta copeptin (median -38% vs. +66%, p < 0.001), day 2 (median 3.1 vs. 4.0 pmol/L, p = 0.021), and week 2 levels (median 2.5 vs. 3.2 pmol/L, p = 0.021) compared with the non-AVP-D group. Delta copeptin (area under the curve 0.826, p = 0.001) demonstrated the best diagnostic performance for AVP-D with an optimal cutoff of < -10% (sensitivity 100%, specificity 76.2%). All AVP-D patients exhibited negative delta copeptin. Week 2 copeptin (area under the curve 0.891, p = 0.011) predicted permanent AVP-D best with an optimal cutoff of < 2.6 pmol/L (sensitivity 100%, specificity 66.7%).
conclusionsDelta copeptin—the change in copeptin levels from T0 (periextubation) to T1 (2–4 h post-surgery)—predicted AVP-D after TSS. We recommend measuring copeptin immediately after surgery and repeat at 2–4 h. Patients with positive delta copeptin were unlikely to develop AVP-D. A copeptin value > 2.6 pmol/L at week 2 ruled out permanent AVP-D.
Indexed as
Identifiers
42050036What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.